查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589465

糖尿病視網膜病變市場：按類型、管理分類 - 2025-2030 年全球預測

Diabetic Retinopathy Market by Type (Non-proliferative DR, Proliferative DR), Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年糖尿病視網膜病變市值為3.7638億美元，預計到2024年將達到4.4148億美元，複合年成長率為17.69%，到2030年將達到11.772億美元。

糖尿病視網膜病變（DR）是一種由糖尿病引起的眼科疾病，會影響視網膜血管並導致視力障礙和失明。此市場分析的範圍包括目前的診斷技術、藥物治療、雷射治療以及旨在管理或治療 DR 的預防性治療方法。全球糖尿病人口不斷成長以及糖尿病相關併發症發生率不斷增加，因此需要有效的 DR 管理。早期發現和早期管理對於預防嚴重視力喪失至關重要，使其成為一個具有豐富應用選擇的領域，包括眼科診所、醫院、門診手術中心和眼科專科病房。主要市場促進因素包括醫學影像處理技術的進步、意識提升舉措以及政府對糖尿病和眼部健康措施的資助。值得注意的是，人工智慧主導的診斷工具和遠端醫療解決方案的開發提供了最新的潛在機會。公司可以從智慧型手機眼底攝影機和穿戴式監測設備等創新技術的投資中受益。然而，由於先進診斷設備的成本高昂、缺乏熟練的醫療保健專業人員以及進入醫療服務機會有限的農村地區的挑戰，市場成長面臨限制。此外，監管挑戰和治療方案的潛在副作用正在阻礙市場擴張。儘管存在這些挑戰，但針對每位患者 DR 的獨特進展，微創治療方案和個人化醫療方法仍有創新的機會。競爭激烈的市場需要藥物配方和診斷技術的持續創新，重點是成本效率和可近性。與科技公司和研究機構的夥伴關係可以產生重要的見解，加速突破，並使公司處於視力保健市場的前沿。總體而言，平衡技術進步與可負擔性和可近性對於佔領新興市場和解決未滿足的需求至關重要。

主要市場統計
基準年[2023] 37638萬美元
預測年份 [2024] 44148萬美元
預測年份 [2030] 11.772 億美元
複合年成長率（%） 17.69%

市場動態：快速發展的糖尿病視網膜病變市場的關鍵市場洞察

供需的動態交互作用正在改變糖尿病視網膜病變市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球糖尿病盛行率上升
    • 提高對糖尿病管理和護理的認知
    • 政府推動糖尿病管理的舉措
  • 市場限制因素
    • 缺乏熟練的眼科醫生
  • 市場機會
    • 不斷引進先進的治療方法和藥物
    • 治療糖尿病黃斑部水腫聯合治療的出現
  • 市場挑戰
    • 核准糖尿病視網膜病變治療需要時間

波特五力：駕馭糖尿病視網膜病變市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解糖尿病視網膜病變市場的外部影響

外部宏觀環境因素在塑造糖尿病視網膜病變市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解糖尿病視網膜病變市場的競爭格局

對糖尿病視網膜病變市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣糖尿病視網膜病變市場供應商的績效評估

FPNV定位矩陣是評估糖尿病視網膜病變市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製糖尿病視網膜病變市場的成功之路

糖尿病視網膜病變市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球糖尿病盛行率正在上升
      • 提高對糖尿病管理和護理的認知
      • 政府推動糖尿病管理的舉措
    • 抑制因素
      • 缺乏熟練的眼科醫生
    • 機會
      • 持續介紹先進的糖尿病視網膜病變治療方法和藥物
      • 聯合療法治療糖尿病黃斑部水腫的出現
    • 任務
      • 糖尿病視網膜病變藥物的核准過程需要時間
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 糖尿病視網膜病變市場：依類型

  • 非增殖性DR
  • 增殖性DR

第7章經營團隊的糖尿病視網膜病變市場

  • 抗VEGF治療
  • 眼內類固醇注射
  • 雷射手術
  • 玻璃體切除手術

第8章北美與南美糖尿病視網膜病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區糖尿病視網膜病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲糖尿病視網膜病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • BCN PEPTIDES, SAU
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Kowa Company, Ltd.
  • Novartis AG
  • Opthea Limited
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics Inc.
Product Code: MRR-742BD517D2EC

The Diabetic Retinopathy Market was valued at USD 376.38 million in 2023, expected to reach USD 441.48 million in 2024, and is projected to grow at a CAGR of 17.69%, to USD 1,177.20 million by 2030.

Diabetic Retinopathy (DR) is a diabetes-induced eye condition that affects the retinal blood vessels and can lead to vision impairment and blindness. The scope of analysis within this market includes current diagnostic technologies, pharmaceutical treatments, laser therapies, and preventive care methods aimed at managing or treating DR. The necessity for efficient DR management arises from the growing global diabetic population and the increasing incidence of diabetes-related complications. Early detection and management are critical in preventing severe vision loss, making this an area rich with application options across eye care clinics, hospitals, outpatient surgical centers, and specialized ophthalmology wards. Key market growth drivers include advancements in medical imaging technologies, heightened awareness initiatives, and government funding for diabetes and eye health initiatives. Notably, the development of AI-driven diagnostic tools and telemedicine solutions presents the latest potential opportunities. Companies can benefit by investing in innovative technologies such as smartphone fundus cameras and wearable monitoring devices. However, market growth faces limitations driven by high costs of advanced diagnostic devices, lack of skilled healthcare professionals, and challenges in reaching rural areas with limited access to healthcare services. Furthermore, the market's expansion is hindered by regulatory challenges and potential side effects of treatment options. Despite these challenges, there are opportunities in the innovation of minimally invasive treatment options and personalized medicine approaches, targeting the unique progression of DR in individual patients. The market's competitive nature demands continuous innovation in drug formulations and diagnostic techniques, emphasizing cost-efficiency and accessibility. Fostering partnerships with technology firms and research institutions can generate significant insights and foster breakthroughs, thus positioning companies at the forefront of the vision care market. Overall, balancing technological advancements with affordability and accessibility will be crucial in capturing emerging markets and addressing the substantial unmet needs in diabetic retinopathy care.

KEY MARKET STATISTICS
Base Year [2023] USD 376.38 million
Estimated Year [2024] USD 441.48 million
Forecast Year [2030] USD 1,177.20 million
CAGR (%) 17.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Retinopathy Market

The Diabetic Retinopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetes globally
    • Increasing awareness associated with diabetic management and care
    • Government initiatives to promote the diabetes management
  • Market Restraints
    • Dearth of skilled ophthalmologists
  • Market Opportunities
    • Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • Emergence of combine therapies for treatment of diabetic macular edema
  • Market Challenges
    • Time consuming approval process for diabetic retinopathy drugs

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Retinopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Retinopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Retinopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Retinopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Retinopathy Market

A detailed market share analysis in the Diabetic Retinopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Retinopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Retinopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Retinopathy Market

A strategic analysis of the Diabetic Retinopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, BCN PEPTIDES, S.A.U., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Kowa Company, Ltd., Novartis AG, Opthea Limited, Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sirnaomics Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-proliferative DR and Proliferative DR.
  • Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes globally
      • 5.1.1.2. Increasing awareness associated with diabetic management and care
      • 5.1.1.3. Government initiatives to promote the diabetes management
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
      • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Retinopathy Market, by Type

  • 6.1. Introduction
  • 6.2. Non-proliferative DR
  • 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

  • 7.1. Introduction
  • 7.2. Anti-VEGF Therapy
  • 7.3. Intraocular Steroid Injection
  • 7.4. Laser Surgery
  • 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alimera Sciences, Inc.
  • 2. Allergan PLC
  • 3. Ampio Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. BCN PEPTIDES, S.A.U.
  • 7. F. Hoffmann-La Roche AG
  • 8. Kodiak Sciences Inc.
  • 9. Kowa Company, Ltd.
  • 10. Novartis AG
  • 11. Opthea Limited
  • 12. Oxurion NV
  • 13. Pfizer Inc.
  • 14. Regeneron Pharmaceuticals Inc.
  • 15. Sirnaomics Inc.

LIST OF FIGURES

  • FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC RETINOPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC RETINOPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY INTRAOCULAR STEROID INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 101. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023